Back to Search Start Over

Self-Maintaining CD103 + Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses.

Authors :
Abd Hamid M
Colin-York H
Khalid-Alham N
Browne M
Cerundolo L
Chen JL
Yao X
Rosendo-Machado S
Waugh C
Maldonado-Perez D
Bowes E
Verrill C
Cerundolo V
Conlon CP
Fritzsche M
Peng Y
Dong T
Source :
Cancer immunology research [Cancer Immunol Res] 2020 Feb; Vol. 8 (2), pp. 203-216. Date of Electronic Publication: 2019 Nov 26.
Publication Year :
2020

Abstract

Enrichment of CD103 <superscript>+</superscript> tumor-infiltrating T lymphocytes (TIL) is associated with improved outcomes in patients. However, the characteristics of human CD103 <superscript>+</superscript> cytotoxic CD8 <superscript>+</superscript> T cells (CTL) and their role in tumor control remain unclear. We investigated the features and antitumor mechanisms of CD103 <superscript>+</superscript> CTLs by assessing T-cell receptor (TCR)-matched CD103 <superscript>+</superscript> and CD103 <superscript>-</superscript> cancer-specific CTL immunity in vitro and its immunophenotype ex vivo Interestingly, we found that differentiated CD103 <superscript>+</superscript> cancer-specific CTLs expressed the active form of TGFβ1 to continually self-regulate CD103 expression, without relying on external TGFβ1-producing cells. The presence of CD103 on CTLs improved TCR antigen sensitivity, which enabled faster cancer recognition and rapid antitumor cytotoxicity. These CD103 <superscript>+</superscript> CTLs had elevated energetic potential and faster migration capacity. However, they had increased inhibitory receptor coexpression and elevated T-cell apoptosis following prolonged cancer exposure. Our data provide fundamental insights into the properties of matured human CD103 <superscript>+</superscript> cancer-specific CTLs, which could have important implications for future designs of tissue-localized cancer immunotherapy strategies.<br /> (©2019 American Association for Cancer Research.)

Details

Language :
English
ISSN :
2326-6074
Volume :
8
Issue :
2
Database :
MEDLINE
Journal :
Cancer immunology research
Publication Type :
Academic Journal
Accession number :
31771983
Full Text :
https://doi.org/10.1158/2326-6066.CIR-19-0554